The rise in Medicare premiums and deductibles will be offset by a cap on drug prices. The Inflation Reduction Act of 2022, championed by then-President Joe Biden, places a $2,000 annual cap on overall ...
Explore this year's advancements in gastroenterology biosimilars, highlighting key FDA approvals and market dynamics ...
TipRanks on MSN
Sino Biopharm’s oral psoriasis drug TQH3906 delivers biologic-like efficacy in phase II trial
Sino Biopharmaceutical ( ($HK:1177) ) has provided an update. Sino Biopharmaceutical has reported positive Phase II clinical trial results for ...
Vanda Pharmaceuticals (VNDA) stock hit a two-year high on news it filed a FDA application for its psoriasis drug ...
Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small ...
Complete clearance lasts for a very long time due to knockout of resident memory T cells within the skin,’ said the study’s ...
In the second half of his Maui Derm recap, George Martin, MD, founder and program director of the meeting, highlights new ...
Samsung Bioepis Co. Ltd. has announced the marketing approval of Ustekinumab BS Subcutaneous Injection 45mg Syringes 'NIPRO', ...
Libtayo's approval for high-risk cutaneous squamous cell carcinoma offers a new immunotherapy option, targeting PD-1 ...
A phase 3 trial shows that apremilast, an oral phosphodiesterase 4 inhibitor, improves symptoms, disease severity, and ...
Historically, inflammation against self was considered autoimmune, a concept that stems back to the seminal observations by Ehrlich, who described serum factors now known to be autoantibodies produced ...
Back in October, the 2025 Fall Clinical Dermatology Conference showcased some of the most exciting advances in skin disease treatment this year. From pill-based TYK2 inhibitors and durable IL-23 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback